NasdaqCM:DCTHMedical Equipment
Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative
Delcath Systems recently reported publication of subgroup analyses from its phase 3 FOCUS study of the HEPZATO KIT for unresectable metastatic uveal melanoma in the Journal of Cancer Research and Clinical Oncology, detailing efficacy and safety outcomes across multiple patient categories.
The data highlight that patients with lower tumor burden and low or normal LDH experienced meaningfully longer progression-free and overall survival, with many responses emerging only after several...